OnKure (OKUR): Rasio kapitalisasi marang pendapatan

Logo korporat perusahaan OnKure (OKUR)

High patent barriers and stringent FDA oversight limit entry into the oncology inhibitor sector, while the GURU.Markets portal displays revenue multiple dynamics, where captures the current state of the parameter. Investors value the scientific authority of OnKure Therapeutics Inc (OKUR) in the development of targeted PI3K drugs. Supply chain reliability is ensured through the flawless express delivery of chilled research samples.

Kapitalisasi marang pendapatan: onkuretherapeutics.com (OKUR) kanggo 04.07.2022 - 17.11.2026

Rincian analitis perusahaan OnKure Therapeutics Inc (OKUR)

- kuotasi saiki lan rata-rata prakiraan nilai:
Ringkesan analitik perusahaan:onkuretherapeutics.com, OKUR
Produk dadi OnKure

The P/S multiple reflects the market value of the business relative to its total revenue, allowing for an assessment of asset monetization efficiency. Comparing current values with the median P/S helps investors determine the degree of company overvaluation relative to historical norms. For OnKure Therapeutics Inc (OKUR), this indicator is critical as it reflects market expectations for the future commercialization of drugs. A high ratio here is justified by the potential for patent scalability, which could multiply the returns on current R&D expenditures.

Karo sapa OnKure Therapeutics Inc saingan

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|Koefisien rega marang pendapatan Aadi Bioscience|Rasio rega marang pendapatan TScan Therapeutics Inc TCRX|CSBR: Rasio kapitalisasi marang pendapatan|XBIT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (cel-sci.com)|OSTX: Multiplikator P/S|Rega marang dodolan Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANL (Adlai Nortye)|Rasio rega marang pendapatan Veru Pharma (VERU)|Multiplikator P/S Tempest Tx (TPST)|Rasio rega marang pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang pendapatan|Mural Oncology - Multiplikator P/S|KAPA - Multiplikator P/S|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd